In recent groundbreaking research published in the prestigious journal ChemMedChem, a team from Insilico Medicine has unveiled a novel class of highly potent and selectively targeted inhibitors against PKMYT1, a critical serine/threonine kinase implicated in aggressive cancer phenotypes. The study, titled “An Internal Sulfur–Lone Pair Interaction Enabled the Discovery of Potent and Sub-Family Selective PKMYT1 Inhibitors,” pushes the boundaries of medicinal chemistry by embracing unconventional molecular interactions previously underexplored in drug design. This discovery not only exemplifies the power of artificial intelligence in accelerating drug discovery but also opens new avenues for precise kinase subfamily targeting—a long-standing challenge in oncology therapeutics.
PKMYT1 has emerged as an attractive target in oncology due to its crucial role in regulating cell cycle progression, especially in cancers exhibiting CCNE1 amplification. Traditional therapeutic approaches have centered on targeting kinase ATP-binding sites, yet these are notoriously conserved across kinase families, making it difficult to achieve inhibitor selectivity and minimize off-target effects. Existing clinical candidates such as RP-6306 (RE1) show promising inhibition but suffer from limited selectivity margins, with off-target kinase interactions triggering adverse toxicities and limiting clinically achievable dosing. This bottleneck has propelled Insilico’s researchers to explore innovative molecular strategies to surmount these challenges.
At the core of Insilico’s breakthrough lies a sophisticated conformational restriction strategy that harnesses noncovalent sulfur–lone pair interactions. By ingeniously redesigning the core scaffold from a pyrido-pyrrole system to a thiazolyl-pyrazole ring assembly, the molecule exploits an intramolecular interaction between the sulfur atom on the thiazole ring and the nitrogen lone pair on the adjacent pyrazole ring. This interaction enforces a syn-locked, coplanar conformation of the heteroaromatic rings, positioning the molecule ideally within the PKMYT1 active site. Such precision in molecular geometry tuning represents a paradigm shift away from traditional reliance on hydrogen bonding or rigid cyclization strategies.
This new thiazolyl-pyrazole conformation not only enhances affinity through ideal steric complementarity and optimal electronic interactions but also strategically masks hydrogen-bond donors that might otherwise impair physicochemical properties such as solubility and membrane permeability. By effectively balancing binding potency and desirable drug-like attributes, this approach markedly improves the likelihood of translational success—a significant stride in rational drug design methodologies.
The lead compounds from this new chemotype, designated A4 and its active enantiomer A4-ent1, showcase exceptional biochemical and cellular profiles. A4-ent1 demonstrates an IC₅₀ of 2.2 nM against PKMYT1 and remarkably maintains over 100-fold selectivity over WEE1 and other kinases within the same subfamily. This degree of selectivity is unprecedented in the domain and addresses a major hurdle that has hindered previous clinical candidates’ progression.
Functionally, these compounds robustly inhibit CDK1 phosphorylation, a downstream effector modulated by PKMYT1, thereby impairing cell cycle progression. Their antiproliferative efficacy was confirmed across a spectrum of CCNE1-amplified cancer cell lines, including HCC1569, Ovcar3, and MKN1, highlighting their therapeutic potential in genetically defined tumor contexts. Notably, the compounds exhibit minimal activity on non-amplified lines, underscoring their precision and limiting off-target cytotoxicity.
Pharmacokinetic and physicochemical evaluations reveal significant improvements over earlier scaffolds. Compound A4 displays enhanced permeability in Caco-2 cell assays, indicating superior potential for oral bioavailability. Its aqueous solubility at physiological pH is nearly five times greater than that of RE1, which is critical for formulation and systemic exposure. Moreover, the compounds exhibit reduced metabolic clearance as demonstrated by liver microsome stability assays, suggesting a favorable in vivo pharmacokinetic profile conducive to sustained therapeutic levels.
The innovation showcased by Insilico demonstrates that previously underutilized molecular forces such as sulfur–lone pair interactions can surpass classical binding motifs in both efficacy and selectivity. This represents a hallmark example of how deep mechanistic understanding, combined with AI-driven scaffold hopping and conformational control, can redefine the landscape of medicinal chemistry. By masking lipophilic hydrogen bond donors, the molecule attains enhanced permeability and solubility without sacrificing enzymatic potency—a delicate balance rarely achieved in kinase inhibitor discovery.
This work also underscores the transformative role AI technologies play in drug discovery workflows. Insilico’s Chemistry42 platform, powered by generative chemistry algorithms, guided the rational design and optimization of these inhibitors. By integrating computational predictions with experimental validation, the team drastically condensed the development timeline, nominating preclinical candidates rapidly with minimal synthesized entities—a stark improvement over conventional discovery timelines that typically span years and involve thousands of compounds.
Insilico Medicine’s sustained scientific contributions are notable, with over 200 peer-reviewed publications, including six in Nature Portfolio journals since 2024 alone. Their interdisciplinary approach, merging biotechnology, artificial intelligence, and laboratory automation, positions them as pioneers at the forefront of next-generation pharmaceutical innovation. Their recognition in the Nature Index’s “2025 Research Leaders” highlights their global impact in biological and natural sciences.
This new research not only improves understanding of kinase biology and inhibition but also serves as a template for future endeavors targeting other challenging enzymes and protein families. The strategic application of noncovalent molecular interactions, often sidelined in traditional drug design, may inspire similar campaigns across diverse therapeutic areas, ultimately expanding the scope of precision medicine.
In conclusion, the discovery of potent and highly selective PKMYT1 inhibitors via internal sulfur–lone pair interactions sets a new standard in the quest for safer, more effective cancer treatments. This novel approach, underpinned by AI-driven design and meticulous structural innovation, holds promise for overcoming the entrenched challenges of kinase selectivity. As these candidates advance through preclinical pipelines, there is substantial optimism that such strategies will translate into meaningful clinical outcomes for patients with aggressive malignancies driven by cell cycle dysregulation.
Subject of Research: AI-assisted rational design of sub-family selective PKMYT1 kinase inhibitors exploiting internal sulfur–lone pair molecular interactions.
Article Title: An Internal Sulfur–Lone Pair Interaction Enabled the Discovery of Potent and Sub-Family Selective PKMYT1 Inhibitors
News Publication Date: March 26, 2026
Web References: https://dx.doi.org/10.1002/cmdc.202501029
References:
[1] ChemMedChem 2026, 21 (6), e202501029.
[2] J. Med. Chem. 2024, 67 (1), 420–432.
[3] Eur. J. Med. Chem. 2025, 281, 117025.
[4] Bioorg. Med. Chem. 2026, 135, 118582.
[5] Nat. Commun. 2025, 16 (1), 10759.
Image Credits: Insilico Medicine & ChemMedChem
Keywords
Generative AI, Small molecule inhibitors, Molecular chemistry, Drug discovery, Kinase selectivity, Sulfur–lone pair interaction, Conformational restriction, Oncology therapeutics, AI-driven medicinal chemistry, Preclinical candidate development
Tags: AI-driven cancer drug discoveryATP-binding site challenges in kinase inhibitorsCCNE1 amplified cancer therapyInsilico Medicine cancer researchkinase subfamily selective targetingmedicinal chemistry breakthrough in oncologynovel molecular interactions in kinase inhibitionovercoming off-target kinase toxicityPKMYT1 selective inhibitorsprecision oncology therapeuticsserine/threonine kinase inhibitorssulfur-lone pair interactions in drug design
